Next Generation Sequencing (NGS)*, having experienced significant stagnation from 2022 to 2024, is poised for a resurgence. We forecast that the ~$6.4B WW NGS manufacturer market …

The NGS DxBook provides comprehensive demographic, infrastructure, and panel information for both labs performing in-house NGS testing and institutions outsourcing their testing to …

2025年2月27日 · Roche’s Sequencing by Expansion (SBX) platform marks a significant re-entry into the NGS market, positioning the company as a strong high-throughput competitor. Key …

Is this the future of NGS? - Emerging Players on the Horizon: We forecast that #MGI, #Elembio, #UltimaGenomics, and #SingularGenomics will grow 30%+ p.a. from at a combined $400M in …

2024年8月22日 · Decentralized labs offer faster results, enhancing patient care access. Regulatory and cost challenges hinder decentralized NGS adoption. Reimbursement for …

DeciBio’s Analytics division offers numerous data products to support strategic insights, including in clinical diagnostics (the DxBooks), oncology biomarkers, liquid biopsy, NGS, spatial...

Here are five insights from the latest DeciBio Clinical NGS Database. Insight #1: The EU is on par with the US, in terms of per-lab NGS testing. In speaking with other NGS industry observers, …

NGS data analysis, a critical component in deriving meaningful insights from vast genomic datasets, has witnessed a surge in demand, further fueling market growth. As researchers and …

Check out the latest insights by Rishikesh Kayathi and Stephane Budel from our latest NGS DxBook report, specifically focusing on the competitive landscape of sample preparation …

Marking a significant shift, NGS returned to the forefront after five years of spatial omics dominance, propelled by Ultima's promising announcement of an affordable ($100?)